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license (http://creativementia phase may provide new insight for preventive and clinical trials targeting disease specific
pathways.
Methods: We constructed weighted Genetic risk scores, first based on 20 genome-wide significant
AD risk variants and second clustering these variants within pathways. Risk scores were investigated
for their association with AD,mild cognitive impairment, and brain magnetic resonance imaging phe-
notypes including white matter lesions, hippocampal volume, and brain volume.
Results: The risk score capturing endocytosis pathway was significantly associated with mild cogni-
tive impairment (P5 1.44! 1024). Immune response (P5 .016) and clathrin/AP2 adaptor complex
pathway (P5 3.55! 1023) excluding apolipoprotein E also showed modest association with white
matter lesions but did not sustain Bonferroni correction (P 5 9.09! 1024).
Discussion: Our study suggests that the clinical spectrum of early AD pathology is explained by
different biological pathways, in particular, the endocytosis, clathrin/AP2 adaptor complex, and im-
mune response pathways, that are independent of apolipoprotein E (APOE).
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Genetic risk score; Alzheimer’s disease; White matter lesions; Mild cognitive impairment; Endocytosis; Immuneresponse1. Introduction
Alzheimer’s disease (AD) is a heterogeneous and
genetically complex disease with high heritability
(56–79%) [1]. It has been known since the end of thedeclared that no conflict of interest exists.
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commons.org/licenses/by-nc-nd/4.0/).previous century that a polymorphism in the apolipoprotein
E (APOE) gene is the strongest common genetic risk factor
[2–4]. This finding fueled speculations on the role of the
lipid metabolism and cholesterol transport pathway
in AD in addition to the amyloid cascade and
tau phosphorylation mechanism [5,6]. Furthermore,
large-scale genome-wide association studies have
discovered more than 20 novel common genetic variants
that influence the risk of late-onset AD [7–13]. Theseimer’s Association. This is an open access article under the CC BY-NC-ND
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biological pathways including immune response,
endocytosis, cholesterol transport, hematopoietic cell
lineage, protein ubiquitination, hemostasis, clathrin/AP2
adaptor complex, and protein folding, each having a
distinct biological function [14–16]. These eight pathways
are not independent in a way that genes may be part of
more than one biological pathway. For instance, APOE is
part of four of the eight pathways namely cholesterol
transport, hematopoietic cell lineage, clathrin/AP2
adaptor complex, and protein folding pathways; clusterin
(CLU) encoding for apolipoprotein J is involved in six
pathways; phosphatidylinositol binding clathrin assembly
protein (PICALM) and complement factor 1 (CR1) are
involved in two pathways [14–16].
These diverse biological pathways may be responsible for
the clinically heterogeneous manifestation of AD [17–19],
which include endophenotypes such as changes in
structural and functional magnetic resonance imaging
(MRI) phenotypes, most notably hippocampal volume,
total brain volume, and white matter lesions [20–23].
Furthermore, these biological pathways may also modulate
the prodromal stages of AD such as mild cognitive
impairment (MCI) [24–26]. Owing to heterogeneity during
the predementia phase, one important unanswered question
is whether the different biological pathways that are
implicated in AD relate to the pleiotropy of clinical
endophenotypes. We hypothesized that some biological
pathways are involved in distinct clinical endophenotypes,
whereas others may be involved in multiple or even all.
Disentangling the connection of biological pathways to
various aspects of AD-related early pathology may be a
crucial step toward improving our understanding of the
pathogenesis of AD during the predementia stage and a first
step toward a more informative and powerful readout for
preventive and therapeutic trials targeting specific pathways.
The present study aims to capture the different biological
pathways involved in AD using genetic risk scores to
evaluate their role in AD and predementia endophenotypes
including MCI, white matter lesions, and total brain and
hippocampal volume.2. Methods
2.1. Study population
This study included samples from the Rotterdam Study
(RS). The RS is a prospective population-based study [27]
designed to investigate the etiology of age-related disorders.
At the baseline examination in 1990 to 1993, study recruited
7983 subjects 55 years of age from the Ommoord district
of Rotterdam (RS-I). At the baseline entry and after every
3 to 4 years, all the study participants were extensively
interviewed and physically examined at the dedicated
research center. During 2000 to 2001, the baseline cohort
(RS-I) was expanded by adding 3011 subjects 55 yearsof age, who were not yet part of RS-I (RS-II). Second
expansion of RS was performed by recruiting 3932 persons
having 45 years of age during 2006 to 2008 (RS-III). The
study has been approved by the Medical Ethical Committee
of Erasmus Medical Center and by the Ministry of Health,
Welfare and Sport of the Netherlands. Written informed
consents were also obtained from each study participant to
participate and to collect information from their treating
physicians. Details of AD, dementia, and MCI diagnosis
are provided in the Supplementary Information. In the
present study for AD cross-sectional analysis, we included
in total 1270 late-onset AD cases and 7623 controls (age
at last follow-up  65 years and dementia free) whose
follow-up information is complete until 2009 to 2013 in
RS-I, RS-II, and RS-III cohorts. This AD sample includes
1057 incident and 213 prevalent AD cases. For prospective
AD analysis, 10,370 dementia-free (normal) participants
were also included in the study from all three RS cohorts
at their baseline and were subsequently followed until
2009 to 2013, to analyze their progression into AD (average
11 years of follow-up). In the MCI data set, we included 360
MCI cases and 3245 cognitively normal controls from the
first extensive cognitive assessment conducted between
2002 and 2005 in RS-I and RS-II cohorts. MRI was
implemented in 2005 in RS cohorts, and 5899 persons
came for MRI scanning until 2015. After excluding subjects
with stroke and/or dementia (n 5 251) at time of scanning,
poor imaging quality (n 5 313), and missing genotyping
information (n5 814), we retained 4521 cognitively normal
individuals in the MRI sample (Table 1).2.2. Genotyping
Blood was drawn for genotyping from participants of RS
cohorts during their first visit, and DNA genotyping was
performed at the internal genotyping facility of the Erasmus
Medical Center, Rotterdam. All samples were genotyped
with the 550K, 550K duo, or 610K Illumina arrays.
Genotyping quality control criteria include call rate ,95%,
Hardy-Weinberg equilibrium P , 1.0 ! 1026, and minor
allele frequency,1%. Moreover, study samples with excess
autosomal heterozygosity, call rate,97.5%, ethnic outliers,
and duplicate or family relationships were excluded during
quality control analysis. Genetic variants were imputed
from the Haplotype Reference Consortium reference panel
(version 1.0) [28], using the Michigan imputation server
[29]. The server uses SHAPEIT2 (v2.r790) [30] to phase
the genotype data and performs imputation with Minimac 3
software [31]. For this study, we used genetic variants that
had imputation quality (R2). 0.5.2.3. MRI scanning
2.3.1. Image acquisition
MRI scanning is assessed on a 1.5-T MRI unit with a
dedicated eight-channel head coil (Signa HD platform; GE
Table 1
Cohort characteristics
Characteristics RS-I RS-II RS-III Total
AD data set (N) 5854 2062 977 8893
Late-onset AD 1118 134 18 1270
AD free controls 4736 1928 959 7623
Age-of-onset (SD), years 84.58 (6.8) 82.75 (6.7) 78.54 (9.5) 84.30 (6.8)
Age of controls (SD), years 82.87 (6.9) 76.52 (6.4) 69.15 (5.7) 79.53 (8.2)
Female (%) 3526 (60) 1133 (55) 569 (58) 5228 (59)
MCI data set (N) 2178 1427 3605
MCI cases 235 125 - 360
Controls 1943 1302 - 3245
Age (SD), years 74.79 (5.7) 67.53 (6.9) - 71.9 (7.2)
Female (%) 1271(58.4) 786 (55.1) - 2057 (57%)
MRI data set (N) 968 1068 2485 4521
Age (SD), years 78.89 (4.9) 69.34 (5.9) 57.21 (6.4) 64.72 (10.8)
Female (%) 556 (58) 565 (53) 1390 (56) 2511 (56)
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; RS, Rotterdam Study (cohort I, II, and III);
SD, standard deviation.
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dedicated MRI machine in the RS. The MRI protocol was
based on several high-resolution axial sequences, including
a T1-weighted (slice thickness 0.8 mm), T2-weighted
(1.6 mm), and fluid-attenuated inversion recovery sequence
(2.5 mm). A detailed description of the MRI protocol is
described previously [32].
2.3.2. Image processing
We excluded 251 persons with stroke and/or dementia
from the total 5899 subjects because this may affect image
processing. All T1 images were segmented into the
supratentorial gray matter, white matter, and cerebrospinal
fluid using a k-nearest neighbor algorithm [33].White matter
lesions were segmented based on T1 tissue maps and an
automatically detected threshold for the intensity of
fluid-attenuated inversion recovery scans [34]. The
hippocampus was segmented using a fully automated
method, as described previously [35]. Semiquantitative
MRI postprocessing software was used to measure
intracranial volume and brain volume, which included
Elastix and custom-built software [36]. To calculate
intracranial volume, non–brain tissues (skull, eyes, and
dura) were removed by nonlinearly registering all brain
scans to a manually created template in which non–brain
tissues were masked [33,36,37]. In all MRI scans, after
visual inspection of all segmentations, additional 313
subjects were excluded because of poor quality.2.4. Statistical analysis
2.4.1. Genetic risk score computation
To construct the risk score, we selected late-onset
AD-associated single-nucleotide polymorphisms (SNPs)
reaching genome-wide significance level (P , 5.0! 1028;
Supplementary Table 1), including one rare TREM2 variant
[7,38]. In common variants, we considered only variants
identified by the International Genomics of Alzheimer’sProject (IGAP) meta-analyses. In addition, we considered
APOE ε4 (rs429358) variant for risk score construction.
From a total of 21 SNPs, the HLA-DRB1-HLA-DRB5
(rs9271192) variant was excluded from risk score calculation
because of its low imputation quality (R25 0.31) in the RS.
This led to a final selection of 20 independent genome-wide
significant AD-associated variants. Weighted genetic risk
scorewas constructed using the effect sizes (log of odds ratio)
of the genome-wide significant variants from the IGAP
meta-analysis [7] as weights and their respective allele
dosages from imputed genotype data of our study cohorts.
Risk score was constructed as the sum of the products of
SNP dosages and their corresponding weights in R software
(https://www.R-project.org/). We constructed genetic risk
score in two ways: (1) combining all 20 selected variants
and (2) clustering the variants into their respective pathways.
2.4.1.1. Combined genetic risk score
Combined genetic risk score (GRS1) was constructed in
two ways, that is, (1) using all the 20 selected SNPs and
(2) excluding the APOE ε4 variant to identify the joint
independent effect of all other genome-wide significant
SNPs.
2.4.1.2. Pathway-specific genetic risk score
For pathway-specific genetic risk score (GRS2), the
genome-wide significant AD SNPs were divided into
pathways (immune response, endocytosis, cholesterol
transport, hematopoietic cell lineage, protein ubiquitina-
tion, hemostasis, clathrin/AP2 adaptor complex, and
protein folding pathway) identified by Jones et al. [16]
(Supplementary Table 2). Classifying genome-wide
significant AD SNPs into pathways, we also used
information from Guerreiro et al. [14], in which the authors
reviewed the possible division of known AD-associated
genes into biological pathways [14]. Furthermore, the
GeneNetwork database (http://genenetwork.nl/) was used
to confirm the allocated pathways. Of the 20 SNPs, 14 could
be clustered into seven nonmutually exclusive pathways
Table 2
Results of association of AD with risk scores
SNP cluster*
Including APOE Excluding APOE
b SE P value b SE P value
GRS1 (combined) 0.73 0.040 6.53! 10274 0.69 0.101 1.12! 10211
Immune response - - - 0.69 0.166 3.20! 1025
Endocytosis - - - 0.75 0.171 1.28! 1025
Cholesterol transport 0.71 0.042 3.22! 10264 0.39 0.219 .077
Hematopoietic cell lineagey 0.73 0.042 5.16! 10266 - - -
Hemostasis - - - 0.50 0.292 .090
Clathrin/AP2 adaptor complex 0.72 0.042 4.68! 10265 0.50 0.236 .036
Protein foldingy 0.72 0.042 2.96! 10264 - - -
Abbreviations: b, regression coefficient; APOE, apolipoprotein E; GRS1, combined genetic risk score; GRS2, pathway-specific genetic risk score; RS, Rot-
terdam Study; SE, standard error; SNP, single-nucleotide polymorphism.
NOTE. Multiple testing correction by Bonferroni [0.05/(5 phenotypes! 11 risk scores); P , 9.09! 1024] was considered significant.
*Logistic regression model adjusted for age and sex in the RS (N 5 1270 cases).
yOnly one SNP available in excluding APOE GRS2.
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constructed GRS2 with and without the APOE ε4 variant.
The APOE ε4 variant was grouped under four pathways
including cholesterol transport [14], hematopoietic cell
lineage, clathrin/AP2 adaptor complex, and protein folding
[16]. GRS2 was constructed for only those pathways which
could be assigned at least two SNPs; therefore, protein
ubiquitination pathway, which contained only one SNP,
was excluded from all analyses, while hematopoietic cell
lineage and protein folding pathways were also not
considered in the analyses excluding the APOE ε4 variant.
2.4.2. Association analyses of GRS1 and GRS2
To test the association of AD and MCI with the risk scores,
we used logistic regression analysis in R software
(www.R-project.org), using disease status as the outcome,
risk scores as predictor, and age and sex as covariates. To assess
the possible inflationof association results betweenADand risk
scores, we repeated the association analysis excluding 625 AD
cases who were part of the IGAP meta-analysis [7] from total
1270 AD cases of the RS cohort. Furthermore, we performed
prospective analysis using the Cox-proportional hazardsmodelTable 3




GRS1 (combined) 0.19 0.075
Immune response - -
Endocytosis - -
Cholesterol transport 0.11 0.082
Hematopoietic cell lineagey 0.09 0.084
Hemostasis - -
Clathrin/AP2 adaptor complex 0.12 0.082
Protein foldingy 0.10 0.083
Abbreviations: b, regression coefficient; APOE, apolipoprotein E; GRS1, c
SE, standard error; SNP, single-nucleotide polymorphism; RS, Rotterdam Study.
NOTE. Multiple testing correction by Bonferroni [0.05/(5 phenotypes! 11 ris
*Logistic regression model adjusted for age and sex in the RS (N 5 360 cases
yOnly one SNP available in excluding APOE pathway-based GRS2.(N5 1057 incident AD cases) in R software using “survival”
package [39] and reported results as hazard ratio (HR) per
1–standard deviation increase in risk score and 95% confidence
interval. The association of single variants with AD and MCI
was assessed using a logistic regression model adjusted for
age and sex. Results of association analyses were reported as
unstandardized regression coefficient and P values.
To test the association of MRI phenotypes including total
brain volume, white matter lesions, and hippocampal volume
with the risk scores,we used linear regression adjusted for age,
sex, and intracranial volume in MRI scans. Single-variant
association analysis was also performed for MRI phenotypes.
Bonferroni correction [0.05/(11 risk scores! 5 phenotypes);
P5 9.09! 1024] was used to correct for multiple testing.3. Results
3.1. Association of the GRS1 with AD, MCI, and MRI
endophenotypes
The risk score containing all SNPs, that is, GRS1 both
including APOE ε4 (effect 5 0.73, P 5 6.53 ! 10274)Excluding APOE
P value b SE P value
.012 0.59 0.179 9.51! 1024
- 0.46 0.295 .116
- 1.16 0.305 1.44! 1024
.164 0.39 0.392 .322
.269 - - -
- 20.08 0.524 .872
.128 0.72 0.423 .089
.218 - - -
ombined genetic risk score; GRS2, pathway-specific genetic risk score;
k scores); P , 9.09! 1024] was considered significant.
).
Table 4
Results for association of risk scores with MRI phenotypes
SNP cluster*




volume Brain volume White matter lesions
Hippocampal
volume Brain volume
b SE P b SE P b SE P b SE P b SE P b SE P
GRS1 (combined) 0.012 0.016 .448 20.001 0.016 .929 0.002 0.007 .806 0.059 0.037 .114 20.009 0.038 .810 20.006 0.016 .724
Immune response - - - - - - - - - 0.149 0.062 .016 20.024 0.062 .706 20.010 0.026 .692
Endocytosis - - - - - - - - - 0.071 0.062 .254 20.046 0.063 .462 0.004 0.026 .865
Cholesterol transport 0.005 0.017 .785 0.001 0.017 .964 0.004 0.007 .574 0.063 0.080 .434 0.013 0.080 .875 0.023 0.033 .497
Hematopoietic
cell lineagey
0.002 0.017 .901 0.001 0.017 .976 0.004 0.007 .556 - - - - - - - - -
Hemostasis - - - - - - - - - 0.228 0.108 .034 20.077 0.109 .479 20.009 0.045 .835
Clathrin/AP2 adaptor
complex
0.011 0.017 .507 20.002 0.017 .924 0.003 0.007 .658 0.258 0.088 3.55! 1023 20.077 0.109 .479 20.009 0.045 .835
Protein foldingy 0.007 0.017 .700 20.001 0.017 .970 0.004 0.007 .619 - - - - - - - - -
Abbreviations: b, regression coefficient; APOE, apolipoprotein E; GRS1, combined genetic risk score; GRS2, pathway-specific genetic risk score;
MRI, magnetic resonance imaging; SE, standard error; SNP, single-nucleotide polymorphism; RS, Rotterdam Study.
NOTE. Multiple testing correction by Bonferroni [0.05/(5 phenotypes! 11 risk scores); P , 9.09! 1024] was considered significant.
*Linear regression model with MRI phenotype as outcome and risk score as predictor, adjusted for age at MRI scan and sex in the RS (N 5 4521).
yOnly one SNP available in excluding APOE pathway-based GRS2.
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was significantly associated with an increased risk of AD
(Table 2). This association remained significant (APOE
excluding; effect5 0.66, P5 8.45! 1027) after removing
the patients who were included in the IGAP meta-analysis
[7] (Supplementary Table 3). GRS1 was also significantly
associated with progression from normal subjects into AD
patients both including (HR 5 1.69, P 5 6.64 ! 10283)
and excluding APOE ε4 (HR 5 1.27, P 5 4.88 ! 10215;
Supplementary Table 4). GRS1 was associated with MCI
when APOE ε4 was included (effect 5 0.19, P 5 .012),
but the association was stronger when APOE ε4 was
excluded from the analysis (effect 5 0.59, P 5 9.51 !
1024; Table 3); however, these associations did not pass
multiple testing correction. No association of GRS1 was
observed with any of the MRI phenotypes: white matter
lesions, hippocampal volume, and total brain volume
(Table 4).
3.2. Association of the GRS2 with AD
Among GRS2 of which APOE ε4 is a part, cholesterol
transport, hematopoietic cell lineage, clathrin/AP2 adaptor
complex, and protein folding were significantly associated
with AD (effect  0.71, P , 3.22 ! 10264) only when
APOE ε4 was included in the risk scores. Among the
non-APOE pathways, AD was significantly associated
with GRS2 capturing immune response (effect 5 0.69,
P 5 3.20*1025) and endocytosis pathway (effect 5 0.75,
P 5 1.28 ! 1025; Table 2), and association sustained
(immune response: effect 5 0.68, P 5 2.22 ! 1023, and
endocytosis: effect 5 0.79, P 5 5.37 ! 1024) even after
removing the patients who were included in the IGAP
meta-analysis [7] (Supplementary Table 3). GRS2 capturing
immune response (HR 5 1.14, P 5 1.19 ! 1025),endocytosis (HR 5 1.19, P 5 5.16 ! 1028), and APOE
ε4-excluded clathrin/AP2 adaptor complex (HR 5 1.09,
P 5 5.98 ! 1023) pathway showed association with
progression from normal into AD. Both Immune response
and endocytosis pathways were significant after correcting
for multiple testing. GRS2 including APOE ε4 were also
significantly associated with normal-to-AD progression
(HR  1.60, P  1.44 ! 10269; Supplementary Table 4).
Comparatively, except for APOE ε4, and the variants in
CR1 and BIN1 genes, no single variant showed significant
evidence of association with AD (Supplementary Table 5).
The variant rs6733839 in the BIN1 gene partially explains
the association between the endocytosis pathway and AD,
whereas APOE ε4 mainly explains the association of all
pathways of which APOE ε4 is a part.3.3. Association of the GRS2 with MCI
In GRS2, only the endocytosis pathway showed
significant evidence for association (effect 5 1.16,
P 5 1.44 ! 1024; Table 3) with MCI. Although the
significance of the association is similar to that of the overall
risk score (GRS1), the effect estimate is considerably higher
(1.16 vs. 0.59 overall). In the single-variant analysis, the
strongest association of MCI was observed with rs6733839
in the BIN1 gene (effect 5 0.262, P 5 1.12 ! 1023;
Supplementary Table 5). Although this association was not
significant after correcting for multiple testing, however, it
partially explains the association between MCI and GRS2
capturing endocytosis.3.4. Association of the GRS2 with MRI phenotypes
White matter lesions were associated with GRS2
capturing immune response (effect 5 0.15, P 5 .016) and
S. Ahmad et al. / Alzheimer’s & Dementia- (2018) 1-106clathrin/AP2 adaptor complex excluding APOE ε4
(effect 5 0.26, P 5 3.55! 1023). If we consider multiple
testing, both these associations lose significance after
accounting for all tested phenotypes and risk scores. Of
note is that no association of white matter lesions with the
GRS2 capturing the clathrin/AP2 adaptor complex is
observed when APOE ε4 is included in the GRS2
(effect 5 0.011, P 5 .507; Table 4). We did not observe
association of GRS2 with hippocampal volume and total
brain volume. In the single-variant analysis, association of
white matter lesions is seen with variants in PICALM and
CLU genes (P  .05). Hippocampal volume shows
association with variants in BIN1 and CELF1 genes
(P , .05; Supplementary Table 6). None of the single-
variant association sustained Bonferroni correction for
multiple testing.4. Discussion
Combined risk score is significantly associated with AD
and normal-to-AD progression but not with any of the early
features of AD tested in our study including MCI and MRI
markers. However, our pathway-based risk score analysis
shows that the endocytosis pathway significantly associates
with MCI in addition to AD and normal-to-AD progression
(Supplementary Fig. 1).
The association of GRS1 with AD is consistent with other
similar studies on AD [40–42]. However, while others
observed significant association of combined risk score
with MCI [43,44], in our study the association of GRS1
with MCI was not significant after correcting for multiple
testing. We did not find association of GRS1 with any of
the studied MRI endophenotypes. These findings are
consistent with those of Mormino et al. [45] and Lupton
et al. [46]; both studies did not find association of
hippocampal volume with combined GRS1 based on
genome-wide significant AD variants, but Mormino et al.
[45], observed this association only with risk score based
on non–genome wide significant AD variants. The largest
study so far that included the RS, however, reported
significant evidence of association of risk score based on
all genome-wide significant AD variants with hippocampal
volume and total brain volume [47].
This is the first study that addressed the role of specific
pathways in AD and its early clinical manifestations, that
is, MCI and MRI phenotypes. Our study shows that GRS2
based on the immune response pathway was significantly
associated with AD and normal-to-AD progression.
Furthermore, we observed association of immune response
with white matter lesions at MRI, but this association did
not survive Bonferroni correction. The genes clustered in
the immune response pathway (CLU, CRI, INPP5D,
MS4A6A, TREM2, MEF2C, and EPHA1) are mainly
expressed in microglial cells and play a part in the innate
immune response in the central nervous system [48–52].
Microglial cells are also thought to play a role in amyloidplaque clearance [53,54]. It has been hypothesized that the
activation of the immune system and the subsequent
inflammatory response are involved in neuronal damage
including axonal loss and white matter pathology due to
demyelination [55]. White matter lesions are associated
with increased risk of cognitive decline, developing
dementia [21] and AD [22,56]. White matter lesions are
also more frequently observed in AD patients than controls
[57,58].
The most interesting finding of the present study is that
the genes capturing the endocytosis pathway significantly
associate to MCI, AD, and with progression from normal
(dementia free) to AD. This pathway is independent of
APOE and includes the BIN1, PICALM, CD2AP, and
SORL1 genes. We show that the association of GRS1 with
MCI status is mainly attributed to the genes involved in
the endocytosis pathway. Omitting the AD genes not related
to the endocytosis pathway makes the association of the
pathway with MCI even stronger. This suggests that the
endocytosis pathway plays a critical role in an early
prodromal phase of AD. Our findings are in line with
previous studies suggesting the activation of the endocytic
pathway is the earliest reported intracellular manifestation
of AD [59–61]. Furthermore, the effect estimate of the
endocytosis pathway was larger for MCI (1.16) compared
with AD (0.75), suggesting a stronger association with
MCI; however, this difference in effect estimates was not
significant (P 5 .12). The endocytosis pathway is involved
in neuronal uptake of macromolecules and secretory
vesicles during synaptic transmission. As efficient uptake
of extracellular cholesterol is critical for neuronal
functions such as repair, synapse formation, and exon
elongation [62], normal neuronal work needs smooth
functioning of endocytosis pathway [63]. Postmortem
studies have also demonstrated reduced brain cholesterol
levels in the brain areas responsible for memory and
learning, among late-onset AD cases and age-matched
controls [64]. These facts suggest that defects in endocytosis,
which derive the cholesterol uptake, could lead to impaired
neurotransmitter release and synaptic function [65].
Dysfunction in endocytosis can also contribute to
accumulation of abnormal amyloid b (Ab) peptides [66].
Based on this finding, we can suggest that the endocytosis
pathway is a common molecular mechanism between MCI
and AD that starts manifesting at early stages of disease.
Risk contributed by variants clustered in this pathway at
various stages of AD progression can possibly provide
clue about disease trajectory.
Our study further shows association of the clathrin/AP2
adaptor complex pathway with white matter lesions.
Although the association failed to pass the multiple testing,
it is interesting to note that no association was detected with
the combined risk score either in our study or a larger study
performed earlier by Chauhan et al. [47] that included up to
11,550 individuals. This suggests that pathway-based risk
scores may be more sensitive in picking association signals
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variants tagging PICALM and CLU genes cluster in the
clathrin/AP2 adaptor complex pathway. Each variant
independently shows nominal association with white matter
lesions in our analyses, but combining their effect are
additive and improve the strength of the association. There
is a strong evidence that the two proteins encoded by the
genes interact at molecular level [67,68]. PICALM is
involved in VAMP2 trafficking that is a crucial process to
maintain functional integrity of synapses, which are
crucial to cognitive function [69,70]. PICALM is also
found to be expressed in the white matter, and
immunolabeling of human brain tissue shows that
PICALM is mainly found in blood vessel walls [71]. CLU
clustered in the clathrin/AP2 adaptor is involved in efflux
of free insoluble Ab peptides through blood-brain barrier
[72]. Increased plasma levels of CLU were associated with
increased burden of Ab peptides in healthy elderly
population and brain atrophy in AD [73,74] and decreased
integrity of white matter in young adults [75].
Demyelination of white matter is reported to occur even
before the accumulation of Ab plaques and neurofibrillary
tangles [76]. The findings of the present study suggest
that the increased genetic burden of risk variants in
the clathrin/AP2 adaptor complex (clathrin-mediated
endocytosis) and immune response pathway may play a
role in early pathogenesis of AD through white matter
pathology.
Among pathways including APOE (cholesterol transport,
hematopoietic cell lineage, clathrin/AP2 adaptor complex,
and protein folding), significant association with AD and
normal-to-AD progression suggests that APOE ε4 appears
to be the driving genetic factor for these associations.
Our study provides a readout of pathway-based risk score
association with AD and its predementia endophenotypes.
Our findings are important from a clinical perspective as
these will aid in determining whether a certain biological
pathway is involved in a patient. This will permit targeted
interventions based on predicted pathological pathways.
Similar as the case of cardiovascular diseases [77], a
heterogeneous disease treatment can be followed based on
pathway biomarkers (e.g., glucose level, total cholesterol
and high-density lipid levels, and liver enzymes in case of
cardiovascular disease) [78] but rather on genetic basis.
This requires reference pathways and treatment portfolio.
In the meantime, the pathway-based genetic risk score will
allow stratification of patients in clinical trials based on
causal pathways involved in patients. This may improve
both the power and efficiency of future clinical and
preventive trials.
Our study is a step forward to use known genetic and
pathway information for disentangling the mechanisms of
AD, but it has one major limitation that pathway information
is based on known AD variants identified so far. This will
further improve in future with improved genetic risk
information that can better capture the underlying pathways.Another possible limitation of our study is that 625 cases of
RS-I was a part of meta-analysis performed by the IGAP [7],
which can contribute to possible inflation in our results of
association of risk score with AD. However, excluding these
patients, the results of this study largely remained
unchanged.
To conclude, our study provides strong evidence that the
endocytosis pathway is relevant in the prodromal phase of
AD, that is, in subjects withMCI. Furthermore, the pathways
including immune response and clathrin/AP2 adaptor
complex pathways may be relevant for brain-related early
endophenotypes of AD, such as white matter lesions; this,
however, needs further investigation in larger samples.
Interestingly, all the observed associations with early AD
pathology are shown by APOE-excluding pathways. Future
findings from genomic research will improve the quality of
the pathway-specific genetic scores.Acknowledgments
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1. Systematic review: For constructing genetic risk
scores, we classified genome-wide significant Alz-
heimer’s disease risk variants into seven diverse
biological pathways based on literature identified
using Google Scholar and PubMed resources.
2. Interpretation: In a large prospective population-
based cohort, we evaluated the role of pathway-
based genetic risk scores in predementia
endophenotypes including mild cognitive impair-
ment and brain magnetic resonance imaging pheno-
types. Genetic risk scores capturing the endocytosis
pathway was significantly associated with mild
cognitive impairment, and the clathrin/AP2 adaptor
complex pathway also showed evidence of modest
association with white matter lesions. This study
provides a differential role of biological pathways
during the clinically heterogeneous predementia
phase of Alzheimer’s disease.
3. Future directions: In addition to replication of these
findings in a larger independent population, this
research can be extended to include all non–
genome wide significant variants in these pathways.
Furthermore, the results of this study could help to
prioritize targets for early intervention in the disease
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